Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital…
Biotechnology
CN, Taizhou [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 2.54 | 2.54 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -7.41 | 1.39 | 1.50 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | < 0.005 | 2.23 | 2.23 | |
| Cash | 0.00 | 1.75 | 1.75 | |
| Capex | 0.00 | -0.11 | -0.11 | |
| Free Cash Flow | 0.00 | -0.39 | -0.39 | |
| Revenue | 0.00 | 0.03 | 0.03 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.69 | 0.69 | |
| Operating Margin | 0.00 | -11.29 | -11.29 | |
| ROA | 0.00 | -0.07 | -0.07 | |
| ROE | < 0.005 | -0.14 | -0.14 | |
| ROIC | 0.86 | -0.09 | -0.09 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2179.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2179.HK is permitted for members.
6
Leverage & Liquidity